14-day Premium Trial Subscription Sign Up For FreeGet Free

Aerie Pharmaceuticals Stock Forecast NASDAQ:AERI

$9.57 (-2.35%)

Volume: 961k

Closed: Nov 29, 2021

Hollow Logo Score: -5.333

Aerie Pharmaceuticals Stock Forecast

$9.57 (-2.35%)

Volume: 961k

Closed: Nov 29, 2021

Score Hollow Logo -5.333
Which way will AERI go? Request
Key Stats
P/E Ratio -2.72
Beta 0.81
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
RSImin/max Values: [ 25 - 75 ] RSI14 is 13 and the stock is extremely oversold on RSI14, but some stocks may continue to fall despite the high chance of a correction up. The low RSI lowers the general risk and the stock should be considered if other technical requirements like liquidity and risk-reward are meet.

Big movements in Aerie Pharmaceuticals stock price on Monday moving 11.34% between high and low
(Updated on Nov 29, 2021)

Sell candidate since 2021-11-15 Loss -17.71%

The Aerie Pharmaceuticals stock price fell by -2.35% on the last day (Monday, 29th Nov 2021) from $9.80 to $9.57. and has now fallen 3 days in a row. During the day the stock fluctuated 11.34% from a day low at $9.15 to a day high of $10.19. The price has fallen in 9 of the last 10 days and is down by -19.24% for this period. Volume has increased on the last day by 498 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 961 thousand shares were bought and sold for approximately $9.19 million.

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -27.13% during the next 3 months and, with a 90% probability hold a price between $6.06 and $8.56 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Signals & Forecast

There are few to no technical positive signals at the moment. The Aerie Pharmaceuticals stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $9.87 and $11.41. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Monday, November 08, 2021, and so far it has fallen -24.76%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume rose on falling prices yesterday. This may be an early warning and the stock should be followed more closely.

Support, Risk & Stop-loss

There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.

This stock may move much during the day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $1.04 between high and low, or 11.34%. For the last week, the stock has had a daily average volatility of 7.31%.

Aerie Pharmaceuticals is oversold on RSI14 (13). Some stocks may fall long and hard while being oversold on RSI, but stocks that are heavily oversold on RSI often pose good re-bounce chance and played well it can be a buy candidate.

Our recommended stop-loss: We hold an negative evaluation for this stock. No stop-loss is set.

Is Aerie Pharmaceuticals stock A Buy?

Aerie Pharmaceuticals holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Sell to a Strong Sell candidate.

Current score: -5.333

Predicted Opening Price for Aerie Pharmaceuticals of Tuesday, November 30, 2021

The predicted opening price is based on yesterday's movements between high, low, and the closing price.

Fair opening price November 30, 2021 Current price
$9.64 $9.57 (Undervalued)
Strong Sell Candidate Downgraded

Remember To Visit Our YouTube Channel

Analyst Ratings

On Nov 05, 2021 "Needham & Company LLC" gave "$24.00 - $22.00" rating for AERI. The price target was set to $12.13+1.0%.

Volatility and Risk
Daily Average Volatility: 7.31 %
Overall Risk: Very High High Medium Low Very Low
7.31 %
Daily Average Volatility
Overall Risk

Very High
Very Low

Support & Resistance

Resistance: $11.46
Price: $9.57
No Support Found

AERI Insider Trading Show all Trades



Last 100 transactions
Buy: 1 049 226 | Sell: 1 181 465 (Shares)
Date Action Amount Person Type
Nov 11, 2021 Sell 2 162 Hollander David Common Stock
Sep 20, 2021 Buy 102 412 Mcgraw Benjamin F Iii Stock Option (right to buy)
Sep 20, 2021 Buy 34 513 Mcgraw Benjamin F Iii Common Stock
Aug 14, 2021 Sell 877 Staten Christopher Common Stock
Aug 14, 2021 Sell 765 Larocca John Common Stock
Show all Insider Trades


Last 100 transactions
Buy: 1 049 226 | Sell: 1 181 465 (Shares)

Fibonacci Support & Resistance Levels

Level Price Change
Resistance 10.67 11.53 %
10.28 7.39 %
10.03 4.83 %
Current price: 9.57
Support 9.24 -3.45 %
8.99 -6.01 %
8.60 -10.15 %

Accumulated Volume Support & Resistance Levels

Level Price Chg %
Resistance 11.63 21.53 %
11.60 21.21 %
11.46 19.75 %
Current price 9.57
Support 0 .
0 .
0 .

Click to get the best stock tips daily for free!

About Aerie Pharmaceuticals

Aerie Pharmaceuticals Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its product candidates include Rhopressa, a once-daily eye drop, which has completed Phase III registration trials for the reduction of intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Roclatan, a once-dai... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 100 000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE